Benjamin G. Neel
Founder at Aethon Therapeutics, Inc.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Seth Harrison | M | 63 |
Aethon Therapeutics, Inc.
Aethon Therapeutics, Inc. Hospital/Nursing ManagementHealth Services The company, co-founded by venture capital firm Apple Tree Partners and New York University cancer researchers Shohei Koide, Ph.D., and Benjamin G. Neel, Ph.D., unites immunotherapy and targeted therapy to expand the power and promise of both approaches for people living with cancer. Aethon Therapeutics, Inc. is based in New York, NY. Part of NYU Langone Medical Center, Aethon Therapeutics, Inc. is a company that creates neoantigens by design to transform cancer treatments into cures. The company's novel anti-drug-peptide conjugate/mhc antibodies are designed to be used in combination with targeted covalent inhibitors of ras, egfr, and other oncogenic driver mutations to mount immune attacks and selectively kill residual cancer cells, including drug-resistant "persister" cells. The company was founded by Benjamin G. Neel, Shohei Koide. The CEO is Rajesh Chopra. | - |
Rajesh Chopra | M | 63 |
Aethon Therapeutics, Inc.
Aethon Therapeutics, Inc. Hospital/Nursing ManagementHealth Services The company, co-founded by venture capital firm Apple Tree Partners and New York University cancer researchers Shohei Koide, Ph.D., and Benjamin G. Neel, Ph.D., unites immunotherapy and targeted therapy to expand the power and promise of both approaches for people living with cancer. Aethon Therapeutics, Inc. is based in New York, NY. Part of NYU Langone Medical Center, Aethon Therapeutics, Inc. is a company that creates neoantigens by design to transform cancer treatments into cures. The company's novel anti-drug-peptide conjugate/mhc antibodies are designed to be used in combination with targeted covalent inhibitors of ras, egfr, and other oncogenic driver mutations to mount immune attacks and selectively kill residual cancer cells, including drug-resistant "persister" cells. The company was founded by Benjamin G. Neel, Shohei Koide. The CEO is Rajesh Chopra. | - |
Paul da Silva Jardine | M | - |
Aethon Therapeutics, Inc.
Aethon Therapeutics, Inc. Hospital/Nursing ManagementHealth Services The company, co-founded by venture capital firm Apple Tree Partners and New York University cancer researchers Shohei Koide, Ph.D., and Benjamin G. Neel, Ph.D., unites immunotherapy and targeted therapy to expand the power and promise of both approaches for people living with cancer. Aethon Therapeutics, Inc. is based in New York, NY. Part of NYU Langone Medical Center, Aethon Therapeutics, Inc. is a company that creates neoantigens by design to transform cancer treatments into cures. The company's novel anti-drug-peptide conjugate/mhc antibodies are designed to be used in combination with targeted covalent inhibitors of ras, egfr, and other oncogenic driver mutations to mount immune attacks and selectively kill residual cancer cells, including drug-resistant "persister" cells. The company was founded by Benjamin G. Neel, Shohei Koide. The CEO is Rajesh Chopra. | - |
Greg Wolfond | M | - |
Ontario Cancer Institute
| - |
Nam Hai Chua | M | 79 |
The Rockefeller University
| 43 years |
Jean Gariépy | M | - |
Ontario Cancer Institute
| - |
Tong Li | M | 55 |
Ontario Cancer Institute
| 26 years |
Paul Jardine | M | - |
Aethon Therapeutics, Inc.
Aethon Therapeutics, Inc. Hospital/Nursing ManagementHealth Services The company, co-founded by venture capital firm Apple Tree Partners and New York University cancer researchers Shohei Koide, Ph.D., and Benjamin G. Neel, Ph.D., unites immunotherapy and targeted therapy to expand the power and promise of both approaches for people living with cancer. Aethon Therapeutics, Inc. is based in New York, NY. Part of NYU Langone Medical Center, Aethon Therapeutics, Inc. is a company that creates neoantigens by design to transform cancer treatments into cures. The company's novel anti-drug-peptide conjugate/mhc antibodies are designed to be used in combination with targeted covalent inhibitors of ras, egfr, and other oncogenic driver mutations to mount immune attacks and selectively kill residual cancer cells, including drug-resistant "persister" cells. The company was founded by Benjamin G. Neel, Shohei Koide. The CEO is Rajesh Chopra. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Gerald M. Edelman | M | 94 |
The Rockefeller University
| - |
Jack Fishman | M | 93 |
The Rockefeller University
| 31 years |
Gary K. Schoolnik | M | - |
The Rockefeller University
| 3 years |
Francis Barany | M | - |
The Rockefeller University
| 3 years |
Laura Davis | F | - |
The Rockefeller University
| 5 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 10 | 76.92% |
Canada | 3 | 23.08% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Benjamin G. Neel
- Personal Network